Vitamin B12 and Methylmalonic Acid Testing
Customize your policy alerts
Sign up for medical mutual - ohio Policy AHS - G2014 alerts
Get alerted when Policy AHS - G2014 changes without checking for updates manually.
Monitor payer policy activity
Coverage criteria for serum vitamin B12 (total cobalamin), methylmalonic acid (MMA), and related laboratory tests for diagnosing and monitoring vitamin B12 deficiency; governs medical mutual - ohio members and providers ordering these tests.
No material clinical or coverage changes in this revision.
Coverage Criteria for Vitamin B12 and MMA Testing
Total vitamin B12 testing (serum cobalamin)
Covered when ANY of the following are met; testing allowed once every three months:
From policy coverage section.
From policy coverage section.
From policy coverage section.
Methylmalonic acid (MMA) testing
Covered when ANY of the following are met:
Policy: MMA meets coverage criteria in these scenarios (confirmation).
Policy: MMA indicated for metabolic/inborn errors.
Consensus Panel and guideline recommendations.
Not covered tests or uses
The following are explicitly not covered:
Explicit statement in policy.
Explicit statement in policy.
Explicit statement in policy and not covered list.
Policy limitation.
Covered indications per guideline consensus
Covered when testing is supported by guideline‑recommended indications or risk factors
AAFP and guideline recommendations: CBC + serum B12 as initial evaluation.
AAFP, ASMBS and related societies list specific risk factors warranting testing.
ASMBS, BOMSS and other societies recommend baseline and ongoing surveillance.
ADA and Consensus Panel recommendations.
E‑HOD international consortium recommendation.
Medically supported indications
Testing is supported when clinical presentation and/or risk factors align with professional guidance:
Derived from ADA, NICE, Consensus Panel, BMJ guidance in document.
Reflex / second-tier testing
Reflex or second‑tier testing logic:
Consensus Panel and NICE guidance support cascade/reflex testing.
Screening of healthy, asymptomatic individuals for vitamin B12 deficiency is explicitly excluded from coverage and does not meet coverage criteria per the policy.
Routine screening of asymptomatic, average‑risk individuals is not supported by the evidence and is not routinely indicated; the policy and the Doctors of BC guidance both discourage routine B12 testing in patients without symptoms or risk factors.
The BMJ notes that serum biomarkers, including serum B12 and MMA, are unreliable predictors of B12‑responsive neuropathy and that measuring these biomarkers is neither helpful nor indicated to assess or monitor clinical improvement; clinical monitoring of symptoms should guide treatment decisions.
The policy states that homocysteine testing for confirmation of vitamin B12 deficiency and holotranscobalamin testing for screening, testing, or confirmation do not meet coverage criteria and are considered not covered under this policy.
Using vitamin B12 supplementation or testing solely as a strategy to prevent cardiovascular disease is not supported by the evidence; studies show B‑vitamin supplementation lowers homocysteine but does not reduce cardiovascular events, and the policy therefore does not support B12 testing for CVD prevention alone.
Indications That Meet Coverage
Diagnosis or monitoring of vitamin B12 deficiency
Diagnosis or monitoring of vitamin B12 deficiency when signs/symptoms, risk factors, or treatment monitoring present as listed; MMA for confirmation in low‑normal cases and for inborn errors of metabolism.
Initial evaluation: CBC + serum B12; proceed to MMA if indeterminate and suspicion persists (AAFP).
Policy allows total B12 testing during treatment; MMA useful to monitor response.
Policy explicit statements.
Suspected vitamin B12 deficiency based on clinical manifestations
Suspected vitamin B12 deficiency based on clinical manifestations or laboratory findings:
AAFP listed manifestations.
AAFP stepwise testing recommendation.
Preoperative and postoperative monitoring for bariatric surgery patients (RYGB, SG, BPD/DS)
Preoperative and postoperative monitoring for bariatric surgery patients (RYGB, SG, BPD/DS):
ASMBS and BOMSS guidance.
Chronic metformin therapy and patients with diabetes with neuropathy or unexplained anemia
Chronic metformin therapy and patients with diabetes with neuropathy or unexplained anemia:
ADA and Consensus Panel recommendations.
High total homocysteine or suspected remethylation disorders
High total homocysteine or suspected remethylation disorders — pre‑treatment sample collection:
E‑HOD international consortium recommendation (Guidelines for Cobalamin‑related Remethylation Disorders).
Suspected vitamin B12 deficiency based on symptoms or risk factors
Suspected vitamin B12 deficiency based on symptoms or risk factors (dietary restrictions, malabsorption, chronic metformin use, medications, history of bariatric surgery):
NICE, AAFP, ADA and other societies support testing when symptom(s) plus risk factor(s) are present.
Guideline-driven frequency guidance.
Testing Frequency and Monitoring Intervals
Provider Actions, Documentation, and Operational Rules
Pre-treatment sample collection
Pre-treatment sample collection: For cases of suspected remethylation disorders or when total homocysteine is markedly elevated, document that plasma and urine samples for determination of methylmalonic acid (MMA), methionine, folate, and vitamin B12 were obtained before initiating treatment. This is required to ensure accurate biochemical assessment and appropriate interpretation of results.
- Obtain and document plasma and urine samples for MMA, methionine, folate, and vitamin B12 prior to starting therapy in suspected remethylation disorders or when total homocysteine is high.
- Failure to document pre-treatment collection may lead to denial or requests for additional information.
Provider actions — Not specified / Documentation requirements
Not specified: General provider actions — The policy does not require a separate prior authorization process for the listed laboratory tests; however, providers must document clinical indications (signs/symptoms, risk factors, or treatment monitoring) that meet coverage criteria. Routine screening in asymptomatic individuals without risk factors does not meet coverage criteria and may be denied. Requests for homocysteine or holotranscobalamin to confirm B12 deficiency are not covered and will be denied.
- Document clinical signs/symptoms and/or risk factors when ordering B12 or MMA testing (cutaneous, gastrointestinal, hematologic, neurologic, medication history, bariatric surgery, age >75, dietary factors, etc.).
- Requests for vitamin B12 testing for healthy, asymptomatic individuals for screening will be denied.
- Requests for homocysteine testing to confirm vitamin B12 deficiency will be denied.
- Requests for holotranscobalamin testing for screening, testing, or confirmation of vitamin B12 deficiency will be denied.
- No explicit prior authorization requirement is specified in this policy; follow applicable payer or government program rules if present.
Applicable Procedure Codes
Ordering Requirements and Who May Order
Order must be supported by listed clinical indications or risk factors
Orders for B12 or MMA testing must be supported in the chart by the clinical indications or risk factors listed in the policy (signs/symptoms, treatment monitoring, or listed risk factors).
- Policy ordering requirement: orders must be supported by covered indications (III sections).
No explicit restriction on who may order testing
The policy does not restrict who may order these tests; standard clinical practice implies that the clinician responsible for the patient's care (primary care or relevant specialist) should place the order.
- AAFP recommended evaluation and no provider‑type ordering restriction stated in policy; order per clinician managing the patient.
Order tests per clinical context and cited guidelines
Order tests consistent with guideline recommendations: NICE recommends targeted testing based on symptoms plus risk factors; Consensus Panel and ADA provide context‑specific recommendations (e.g., annual testing for chronic metformin users).
- NICE: test when a common symptom plus a common risk factor are present.
- Consensus Panel/ADA: guidance on metabolic marker use and periodic assessment for metformin users.
Services and Uses Not Covered
The following tests and uses are not covered: holotranscobalamin testing for screening, testing, or confirmation; homocysteine testing for confirmation of vitamin B12 deficiency; and screening in healthy, asymptomatic patients.
Routine vitamin B12 screening in asymptomatic, average‑risk individuals is not supported by evidence and is therefore not covered; likewise, the use of B12 testing as a cardiovascular disease prevention strategy is not supported.
The policy does not support using serum biomarkers (serum B12 or MMA) alone to assess or monitor clinical improvement in neuropathy. The BMJ advises basing treatment frequency and clinical decisions on symptoms rather than biomarker normalization.
Definitions and Test Descriptions
Background and Evidence Context
Vitamin B12 (cobalamin) is essential for hematologic, neurologic, and DNA synthesis functions; deficiency can produce hematologic abnormalities and neuropsychiatric or neurologic manifestations that may be reversible if identified and treated early. Methylmalonic acid (MMA) accumulates when B12 is unavailable and serves as an indicator of functional B12 deficiency, while holotranscobalamin represents the metabolically active fraction but is not covered for routine clinical use in this policy.
Revision History
Reviewed and updated background, guidelines, recommendations, and evidence references; literature review did not require changes to coverage criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.